These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 35448891)

  • 21. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin.
    Clark GT
    Phys Med Rehabil Clin N Am; 2003 Nov; 14(4):727-48. PubMed ID: 14580034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Botulinum Toxin Treatment of Motor Disorders in Parkinson Disease-A Systematic Review.
    Jabbari B; Comtesse SM
    Toxins (Basel); 2023 Jan; 15(2):. PubMed ID: 36828396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Movement disorders of the mouth: a review of the common phenomenologies.
    Ghadery CM; Kalia LV; Connolly BS
    J Neurol; 2022 Nov; 269(11):5812-5830. PubMed ID: 35904592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripherally induced oromandibular dystonia.
    Sankhla C; Lai EC; Jankovic J
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):722-8. PubMed ID: 9810945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
    Karp BI; Alter K
    Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidisciplinary management of a partially edentulous patient with oromandibular dystonia: A clinical report.
    Sakar O; Matur Z; Mumcu Z; Sesen P; Oge E
    J Prosthet Dent; 2018 Aug; 120(2):173-176. PubMed ID: 29429838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group.
    Berardelli A; Formica A; Mercuri B; Abbruzzese G; Agnoli A; Agostino R; Caraceni T; Carella F; De Fazio G; De Grandis D
    Ital J Neurol Sci; 1993 Jun; 14(5):361-7. PubMed ID: 8354632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vada maker's dystonia - A new task-specific focal dystonia.
    Cherian A; Divya KP
    Parkinsonism Relat Disord; 2020 Aug; 77():85-86. PubMed ID: 32653841
    [No Abstract]   [Full Text] [Related]  

  • 31. Focal limb dystonia and tremor: Clinical update.
    Murgai AA; Jog M
    Toxicon; 2020 Mar; 176():10-14. PubMed ID: 31965968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Botulinum toxin for treatment of the focal dystonia].
    Nakamura Y
    Rinsho Shinkeigaku; 2017 Jul; 57(7):367-372. PubMed ID: 28652522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic and therapeutic recommendations in adult dystonia: a joint document by the Italian Society of Neurology, the Italian Academy for the Study of Parkinson's Disease and Movement Disorders, and the Italian Network on Botulinum Toxin.
    Romano M; Bagnato S; Altavista MC; Avanzino L; Belvisi D; Bologna M; Bono F; Carecchio M; Castagna A; Ceravolo R; Conte A; Cosentino G; Eleopra R; Ercoli T; Esposito M; Fabbrini G; Ferrazzano G; Lalli S; Mascia MM; Osio M; Pellicciari R; Petrucci S; Valente EM; Valentino F; Zappia M; Zibetti M; Girlanda P; Tinazzi M; Defazio G; Berardelli A
    Neurol Sci; 2022 Dec; 43(12):6929-6945. PubMed ID: 36190683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.
    Colosimo C; Tiple D; Berardelli A
    Neurotox Res; 2012 Nov; 22(4):265-73. PubMed ID: 22359151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Movement, visceral and autonomic disorders: use of botulinum toxin.
    Moore AP
    Hosp Med; 2003 Aug; 64(8):452-9. PubMed ID: 12958755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of oromandibular dystonia with botulinum A toxin: a series of cases.
    Teemul TA; Patel R; Kanatas A; Carter LM
    Br J Oral Maxillofac Surg; 2016 Dec; 54(10):1080-1084. PubMed ID: 27776922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Movement disorders and botulinum toxin in neurology].
    Sangla S; Trocello JM; Bourdain F; Vidal JS; Gallouedec G; Vidailhet M
    Ann Readapt Med Phys; 2003 Jul; 46(6):307-11. PubMed ID: 12928135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oromandibular dystonia associated with SCA36.
    Miyashiro A; Sugihara K; Kawarai T; Miyamoto R; Izumi Y; Morino H; Maruyama H; Orlacchio A; Kawakami H; Kaji R
    Mov Disord; 2013 Apr; 28(4):558-9. PubMed ID: 23390045
    [No Abstract]   [Full Text] [Related]  

  • 39. The Use of Botulinum Toxin for Treatment of the Dystonias.
    Berardelli A; Conte A
    Handb Exp Pharmacol; 2021; 263():107-126. PubMed ID: 31820178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A.
    Chen JJ; Swope DM
    J Clin Psychiatry; 2005 Feb; 66(2):267-8. PubMed ID: 15705018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.